Frequent Inactivation of Cysteine Dioxygenase Type 1 Contributes to Survival of Breast Cancer Cells and Resistance to Anthracyclines

Purpose: Genome-wide DNA methylation analyses have identified hundreds of candidate DNA-hypermethylated genes in cancer. Comprehensive functional analyses provide an understanding of the biologic significance of this vast amount of DNA methylation data that may allow the determination of key epigenetic events associated with tumorigenesis. Experimental Design: To study mechanisms of cysteine dioxygenase type 1 (CDO1) inactivation and its functional significance in breast cancer in a comprehensive manner, we screened for DNA methylation and gene mutations in primary breast cancers and analyzed growth, survival, and reactive oxygen species (ROS) production in breast cancer cells with restored CDO1 function in the context of anthracycline treatment. Results: DNA methylation-associated silencing of CDO1 in breast cancer is frequent (60%), cancer specific, and correlates with disease progression and outcome. CDO1 function can alternatively be silenced by repressive chromatin, and we describe protein-damaging missense mutations in 7% of tumors without DNA methylation. Restoration of CDO1 function in breast cancer cells increases levels of ROS and leads to reduced viability and growth, as well as sensitization to anthracycline treatment. Priming with 5-azacytidine of breast cancer cells with epigenetically silenced CDO1 resulted in restored expression and increased sensitivity to anthracyclines. Conclusion: We report that silencing of CDO1 is a critical epigenetic event that contributes to the survival of oxidative-stressed breast cancer cells through increased detoxification of ROS and thus leads to the resistance to ROS-generating chemotherapeutics including anthracyclines. Our study shows the importance of CDO1 inactivation in breast cancer and its clinical potential as a biomarker and therapeutic target to overcome resistance to anthracyclines. Clin Cancer Res; 19(12); 3201–11. ©2013 AACR.

[1]  A. Meister,et al.  Potent and specific inhibition of glutathione synthesis by buthionine sulfoximine (S-n-butyl homocysteine sulfoximine). , 1979, The Journal of biological chemistry.

[2]  R. Waring,et al.  Plasma cysteine and sulphate levels in patients with motor neurone, Parkinson's and Alzheimer's disease , 1990, Neuroscience Letters.

[3]  C. Gordon,et al.  Abnormal sulphur oxidation in systemic lupus erythematosus , 1992, The Lancet.

[4]  P. Emery,et al.  Sulfate metabolism is abnormal in patients with rheumatoid arthritis. Confirmation by in vivo biochemical findings. , 1994, The Journal of rheumatology.

[5]  J. Herman,et al.  Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[6]  C. Tormos,et al.  Antioxidant enzyme activities and the production of MDA and 8-oxo-dG in chronic lymphocytic leukemia. , 2001, Free radical biology & medicine.

[7]  J. Herman,et al.  Dependence of histone modifications and gene expression on DNA hypermethylation in cancer. , 2002, Cancer research.

[8]  Bert Vogelstein,et al.  DNMT1 and DNMT3b cooperate to silence genes in human cancer cells , 2002, Nature.

[9]  E. Park,et al.  Taurine: new implications for an old amino acid. , 2003, FEMS microbiology letters.

[10]  L. Behrend,et al.  Reactive oxygen species in oncogenic transformation. , 2003, Biochemical Society transactions.

[11]  Fatima Mechta-Grigoriou,et al.  JunD Reduces Tumor Angiogenesis by Protecting Cells from Oxidative Stress , 2004, Cell.

[12]  M. Kulesz-Martin,et al.  Destructive cycles: the role of genomic instability and adaptation in carcinogenesis. , 2004, Carcinogenesis.

[13]  Gong Yang,et al.  Activation of Antioxidant Pathways in Ras-Mediated Oncogenic Transformation of Human Surface Ovarian Epithelial Cells Revealed by Functional Proteomics and Mass Spectrometry , 2004, Cancer Research.

[14]  K. Kinzler,et al.  Cancer genes and the pathways they control , 2004, Nature Medicine.

[15]  Peng Huang,et al.  ROS stress in cancer cells and therapeutic implications. , 2004, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[16]  S. Batra,et al.  Lipid peroxidation, free radical production and antioxidant status in breast cancer , 2004, Breast Cancer Research and Treatment.

[17]  S. Baylin,et al.  DNA methylation and gene silencing in cancer , 2005, Nature Clinical Practice Oncology.

[18]  Jinsong Liu,et al.  Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate. , 2006, Cancer cell.

[19]  Wen-Sheng Wu.  The signaling mechanism of ROS in tumor progression , 2007, Cancer and Metastasis Reviews.

[20]  Tae-You Kim,et al.  Epigenomic profiling reveals novel and frequent targets of aberrant DNA methylation-mediated silencing in malignant glioma. , 2006, Cancer research.

[21]  P. Schumacker,et al.  Reactive oxygen species in cancer cells: live by the sword, die by the sword. , 2006, Cancer cell.

[22]  J. Yates,et al.  Adaptation of energy metabolism in breast cancer brain metastases. , 2007, Cancer research.

[23]  F. Meyskens,et al.  UC Irvine UC Irvine Previously Published Works Title Reactive oxygen species : a breath of life or death ? , 2007 .

[24]  T. Mikkelsen,et al.  Genome-wide maps of chromatin state in pluripotent and lineage-committed cells , 2007, Nature.

[25]  M. Maroney,et al.  Cysteine dioxygenase: structure and mechanism. , 2007, Chemical communications.

[26]  Z. Rao,et al.  An Insight into the Mechanism of Human Cysteine Dioxygenase , 2007, Journal of Biological Chemistry.

[27]  J. Dominy,et al.  Overexpression of cysteine dioxygenase reduces intracellular cysteine and glutathione pools in HepG2/C3A cells. , 2007, American journal of physiology. Endocrinology and metabolism.

[28]  Wei Chen,et al.  Comparing the DNA Hypermethylome with Gene Mutations in Human Colorectal Cancer , 2007, PLoS genetics.

[29]  G. Martínez-Sánchez,et al.  Cellular redox status regulates hypoxia inducible factor-1 activity. Role in tumour development. , 2007, Journal of experimental & clinical cancer research : CR.

[30]  J. Dominy,et al.  Cysteine dioxygenase: a robust system for regulation of cellular cysteine levels , 2009, Amino Acids.

[31]  J. Herman,et al.  Epigenetic inactivation of the canonical Wnt antagonist SRY-box containing gene 17 in colorectal cancer. , 2008, Cancer research.

[32]  Peng Huang,et al.  Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? , 2009, Nature Reviews Drug Discovery.

[33]  J. Herman,et al.  Methylation of TFPI2 in stool DNA: a potential novel biomarker for the detection of colorectal cancer. , 2009, Cancer research.

[34]  J. Foekens,et al.  RESEARCH ARTICLE Open Access Research article CDO1 Promoter Methylation is a Biomarker for Outcome Prediction of Anthracycline Treated, Estrogen Receptor-Positive, Lymph Node-Positive Breast Cancer Patients , 2022 .

[35]  C. Ricketts,et al.  Genome-wide DNA methylation profiling of CpG islands in breast cancer identifies novel genes associated with tumorigenicity. , 2011, Cancer research.

[36]  R. Scott,et al.  Long Term Transcriptional Reactivation of Epigenetically Silenced Genes in Colorectal Cancer Cells Requires DNA Hypomethylation and Histone Acetylation , 2011, PloS one.

[37]  P. Grundy,et al.  Gene expression analysis of blastemal component reveals genes associated with relapse mechanism in Wilms tumour. , 2011, European journal of cancer.

[38]  Gangning Liang,et al.  DNA methylation screening identifies driver epigenetic events of cancer cell survival. , 2012, Cancer cell.

[39]  L. Cope,et al.  Biomarkers for detection and prognosis of breast cancer identified by a functional hypermethylome screen , 2012, Epigenetics.

[40]  S. Baylin,et al.  DNMT1 modulates gene expression without its catalytic activity partially through its interactions with histone-modifying enzymes , 2012, Nucleic acids research.